Advanced Bladder Cancer VL

TROPHY-U-01 Results Lead to Accelerated Approval of Sacituzumab Govitecan (Trodelvy) for Pretreated Metastatic Urothelial Carcinoma - Scott Tagawa

Details
Patients with metastatic urothelial carcinoma (mUC) who progress on platinum-based combination chemotherapy (PLT) and checkpoint inhibitors (CPIs) have limited options that offer objective response rates (ORRs) of approximately 10% with a median overall survival (OS) of 7-8 months. Sacituzumab govitecan (Trodelvy) is a TROP-2–directed antibody-drug conjugate with an SN-38 payload that has shown pr...

Practical Considerations for Administering Avelumab Maintenance in Clinical Practice - Petros Grivas and Neeraj Agarwal

Details
In this conversation, Alicia Morgans, MD MPH, Neeraj Agarwal, MD, and Petros Grivas, MD, PhD discuss the clinical trial findings from the JAVELIN Bladder 100 trial and how-to treat with chemotherapy followed by avelumab maintenance. They highlight the importance of this to the treatment algorithm of metastatic urothelial carcinoma and highlight a recent publication in Cancer Treatment Reviews on a...

Voluntary Withdrawal In The US of Durvalumab and of Atezolizumab in Metastatic Urothelial Carcinoma - Petros Grivas

Details
In February 2021 AstraZeneca announced the voluntary withdrawal of the Imfinzi (durvalumab) indication in the US for previously treated adult patients with locally advanced or metastatic bladder cancer. In March 2021, Genentech announced the voluntary withdrawals of Tecentriq® (atezolizumab) for the treatment of prior-platinum treated metastatic urothelial carcinoma. Petros Grivas and Alicia Morga...

Characterization of The Genomic Landscape of Post-Neoadjuvant Chemotherapy in MIBC Patients- Andrew Lenis

Details
Currently, the standard of care for muscle-invasive bladder cancer is neoadjuvant chemotherapy followed by radical cystectomy. Patients with residual disease after neoadjuvant chemotherapy have an especially poor prognosis. Unfortunately, there's no standard adjuvant therapy for these patients. Andrew Lenis joins Ashish Kamat emphasizing that additional therapeutic options are needed, and understa...

Metastatic and Muscle-Invasive Bladder Cancer European Association of Urology (EAU) Guidelines - J. Alfred Witjes

Details
Alfred Witjes, MD, PhD, a member of the international multidisciplinary panel of bladder cancer experts for the European Association of Urology (EAU) Guidelines on muscle-invasive and metastatic bladder cancer joins Ashish Kamat, MD, MBBS, in a discussion summarizing the 2020 updated guidelines. Professor Witjes highlights several updates including variant histologies, the best surgical approach f...

Molecular Changes Associated with Treatment Response in Muscle-Invasive Bladder Cancer Patients Treated with Cisplatin-Based Chemotherapy - Lars Dyrskjøt

Details
Cisplatin-based chemotherapy is recommended in both the neoadjuvant and the first-line setting. The inability to predict which patients would respond to chemotherapy, presents a major clinical problem, as there is a significant overtreatment of patients who do not respond. Lars Dyrskjøt joins Ashish Kamat to discuss a Nature Communications publication titled, Molecular correlates of cisplatin-base...

Two-year JAVELIN Solid Tumor Data Phase 1 Final Results - Andrea Apolo

Details
The anti-PD-L1 avelumab in urothelial carcinoma—A discussion with investigator Dr Andrea Apolo. The JAVELIN Solid Tumor phase 1, open-label, dose-escalation trial investigated avelumab, a human monoclonal anti-PD-L1 antibody (anti-PD-L1), in patients with selected tumor indications (eg, NSCLC, breast cancer, colorectal cancer). Pooled analysis of two JAVELIN cohorts that included patients with adv...

Comparing Nab-Paclitaxel and Paclitaxel in Platinum-Refractory Bladder Cancer - Srikala Sridhar

Details
Beyond Endpoints: An interview with Dr Srikala Sridhar, study chair of the BL12 trial Investigator-initiated trials (IITs) often tackle important questions that are not addressed elsewhere. [transcript] Compared with a pharmaceutical company–managed trials, benefits of IITs include generating data in a real-world setting and resolving issues that confound physicians in daily practice. A recent ope...

Implications for Reducing Disparities in Muscle-Invasive Bladder Cancer - Samuel Washington III

Details
Black individuals with muscle-invasive bladder cancer (MIBC) experience 21% lower odds of guideline-based treatment (GBT). Differences in treatment account for 35% of observed Black-White differences in survival. Samuel Washington III, MD, MAS joins Ashish Kamat, MD, MBBS, to highlight this data published in Cancer Medicine. Low GBT levels demonstrated an "under-allocation" of GBT to those who nee...

Guidelines for Advanced Urothelial Carcinoma in First-line Treatment for Patients Ineligible or Unfit for Cisplatin - Michiel S. Van der Heijden

Details
Michiel Van der Heijden MD, PhD, joins Ashish Kamat, MD, MBBS discussing the evolution of the guidelines for advanced urothelial cancer. Michiel Van der Heijden provides a concise summary of the European Association of Urology Guidelines and the ESMO guidelines, contrasting statements between the two for patients in first-line treatment who are ineligible to receive cisplatin-based chemotherapy in...